Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL12 | P48061 | 4/20 | 0.67 |
| ▸ | MAOA | P21397 | 5/20 | 0.66 |
| ▸ | MAOB | P27338 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TERT | O14746 | 1/20 | 0.56 |
| ▸ | SNCA | P37840 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382667 | 1.00 | CXCL12 (0.67) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL30384517 | 0.88 | CXCL12 (0.80) | CXCL12MAOAMAOBMAPTCXCR4 | |
| SCHEMBL25198501 | 0.88 | BACE1 (0.68) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL13869118 | 0.88 | PTGS2 (0.72) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL25209522 | 0.88 | CXCL12 (0.80) | CXCL12MAOAMAOBMAPTCXCR4 | |
| SCHEMBL25221567 | 0.88 | CXCL12 (0.80) | CXCL12MAOAMAOBMAPTCXCR4 | |
| SCHEMBL25200404 | 0.88 | BACE1 (0.68) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL30383358 | 0.88 | BACE1 (0.68) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL25265529 | 0.86 | MAPT (0.76) | CXCL12MAOAMAOBMAPTPOLB | |
| SCHEMBL23951571 | 0.86 | MAPT (0.76) | CXCL12MAOAMAOBMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | CXCL12 399/4885MAOA 1902/4885MAOB 1004/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | CXCL12 287/4885MAOA 3145/4885MAOB 2435/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | CXCL12 287/4885MAOA 3145/4885MAOB 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.